Stomach Neoplasms, Colorectal Neoplasms Stomach Neoplasms, Colorectal Neoplasms
Conditions
Interventions
When performing endoscopic submucosal dissection, PuraLift is injected into the submucosal layer.
Endoscopic Mucosal Resection
Sponsors
Kuribayashi Shiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who are able to obtain written consent from the individual 2) Age 20 years or older at the time of consent 3) Patients with intramucosal neoplastic lesions in the stomach or colon 4) Patients scheduled for endoscopic submucosal dissection as treatment for neoplastic lesions
Exclusion criteria
Exclusion criteria: 1) Patients with residual or recurrent lesions 2) Patients with ulcers in the lesion 3) Patients with multiple lesions for the target procedure (4) Patients with a history of hypersensitivity to any of the components of this product 5) Patients with bleeding tendency 6) Pregnant women or women who wish to become pregnant during the study period and nursing mothers (7) Patients for whom a follow-up visit to the hospital seems impossible (8) Patients with serious hepatic, renal, cardiovascular, or other diseases (9) Other patients deemed inappropriate for this study by the principal investigator or subinvestigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Description and frequency of adverse events and diseases | — |
Secondary
| Measure | Time frame |
|---|---|
| Ease of injection of PuraLift, ease of mucous membrane incision, ease of submcosal dissection, maintenance of mucous membrane elevation, intraoperative incidentals, time required for excision, amount of PuraLift used, postoperative bleeding | — |
Contacts
Public ContactKasuga Kengo
Gunma University Graduate School of Medicine
Outcome results
None listed